Drs. Bramlett, de Rivero Vaccari, Dietrich

InflammaCORE is a biotechnology company focused on the development of novel diagnostics and therapeutics targeting the inflammasome, a key component of the innate immune system. Founded by leading neuroscientists from the University of Miami, the company leverages proprietary technology to detect inflammasome proteins as biomarkers for various inflammatory and neurodegenerative conditions. Their pipeline includes monoclonal antibodies designed to inhibit inflammasome activation, aiming to treat traumatic brain injury, spinal cord injury, and stroke. By focusing on the ASC protein and other inflammasome components, InflammaCORE seeks to provide precision medicine solutions for acute and chronic neuroinflammatory diseases.